Bill has more than 25 years of start-up experience in a broad range of medical specialties intersecting science, technology, clinical medicine, and business strategy. Prior to founding Octave Bioscience, he served as the CEO of Crescendo Bioscience which created novel measurement tools and software in the field of rheumatology. Prior to this, he was the President of Alpha BioPartners, a strategic consulting firm advising the launch of new life sciences companies. While at Alpha BioPartners, Bill created the business plan for Crescendo and co-founded Altheus Therapeutics and Biolytx Pharmaceuticals. Prior to that, he served as the initial CEO of Selexys Pharmaceuticals and interim CEO of Inoveon in ophthalmology. In the 1990s, Bill was Chairman and CEO of UroCor, a urology specialty diagnostics company which he scaled from start-up through IPO. Earlier in his career, he was Vice President of Baxter International’s $1.0 billion Scientific Products Division and held management positions at the American Hospital Supply and Becton Dickinson. He currently serves on the board of directors for CareDx, Navican, Genalyte and CoFactor. Previously he was on the board of Prometheus Laboratories. Bill holds a BS in Business Management from Bob Jones University.
Healthcare diagnostics is at the core of clinical decision making. Early diagnosis can increase the chances of a positive outcome, helping to improve the lives of patients and save payers the costs of further treatment. As health systems move from treatment to prevention, and from volume to value, diagnostics can accelerate this shift. Investment in innovative lab services and technologies is critical in enabling hospitals and healthcare systems to improve efficiencies in the lab, optimize their laboratories to realize gains, and deliver on the imperatives of improving patient outcomes while reducing costs. This session will provide insights from payers that have been actively investing in companies developing innovative lab services and technologies.